Abstract

It is increasingly clear that the nectin family and its immunoreceptors shape the immune response to cancer through several pathways. Yet, even as antibodies against TIGIT, CD96, and CD112R advance into clinical development, biological and therapeutic questions remain unanswered. Here, we review recent progress, prospects, and challenges to understanding and tapping this family in cancer immunotherapy.

Authors	Johnston, Robert J.; Lee, Peter S.; Strop, Pavel; Smyth, Mark J.
Journal	ANNUAL REVIEW OF CANCER BIOLOGY, VOL 5, 2021
Pages	203-219
Volume	5
Date	1/01/2021
Grant ID
Funding Body
URL	http://www.ncbi.nlm.nih.gov/pubmed/?term=10.1146/annurev-cancerbio-060920-084910